ArticleBiophysics and physicobiology2021

Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins.

Atsushi Hijikata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.